T-cell receptor-peptide-MHC class I-CD8 complex (TCR-pMHC-CD8)

The T-cell receptor-peptide-MHC class I-CD8 complex (TCR-pMHC-CD8) is the fundamental molecular assembly required for the recognition of intracellular antigens by cytotoxic CD8+ T cells. This complex forms at the immunological synapse when a T-cell receptor (TCR) and its CD8 co-receptor on a T lymphocyte bind to a specific peptide fragment presented by a Major Histocompatibility Complex class I (MHC I) molecule on the surface of a target cell, such as a dendritic cell or a tumor cell (Source: Janeway's Immunobiology). The CD8 co-receptor stabilizes the interaction by binding to the non-polymorphic alpha-3 domain of the MHC I molecule, which significantly enhances the sensitivity of T cells to low-abundance antigens (Source: PDB 1AKJ). In oncology, this complex is the primary target for TCR-engineered T-cell therapies (TCR-T) and bispecific T-cell engagers that utilize TCR-like binding domains to redirect T-cell killing toward tumor-specific peptides (Source: Nature Reviews Drug Discovery, 2021). However, tumor cells frequently employ immune evasion strategies, such as the downregulation of MHC I or the expression of inhibitory ligands, to disrupt this complex's formation and function (Source: PubMed 30241496). Therapeutic interventions aim to restore or bypass these defects to trigger robust anti-tumor immune responses. Safety concerns associated with targeting this complex include cytokine release syndrome and potential on-target, off-tumor toxicities if the targeted peptide is also presented by healthy tissues (Source: FDA Label for Kimmtrak).

Other names

TCR-pMHC complexCD8-MHC-TCR interactionTrimolecular complexImmunological synapseClass I MHC-restricted TCR complex

The complex facilitates MHC-restricted antigen recognition, leading to the activation of CD8+ cytotoxic T lymphocytes and the subsequent lysis of target cells presenting specific peptide antigens.